James Quigley
Stock Analyst at Goldman Sachs
(1.09)
# 3,833
Out of 5,182 analysts
26
Total ratings
33.33%
Success rate
-0.27%
Average return
Main Sectors:
Stocks Rated by James Quigley
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NVO Novo Nordisk | Downgrades: Neutral | $63 → $41 | $44.87 | -8.62% | 2 | Mar 2, 2026 | |
| KYMR Kymera Therapeutics | Maintains: Overweight | $73 → $127 | $82.71 | +53.55% | 7 | Dec 9, 2025 | |
| NVS Novartis AG | Downgrades: Sell | $119 → $118 | $145.50 | -18.90% | 2 | Sep 12, 2025 | |
| SNY Sanofi | Initiates: Neutral | $65 | $43.36 | +49.91% | 1 | Mar 21, 2025 | |
| GRFS Grifols | Maintains: Neutral | $10 → $11 | $8.27 | +26.96% | 1 | Dec 5, 2023 | |
| GLPG Galapagos NV | Maintains: Equal-Weight | $42 → $40 | $28.39 | +40.89% | 10 | Aug 7, 2023 | |
| EVO Evotec SE | Upgrades: Overweight | $12 → $16 | $3.20 | +400.00% | 3 | Jun 23, 2023 |
Novo Nordisk
Mar 2, 2026
Downgrades: Neutral
Price Target: $63 → $41
Current: $44.87
Upside: -8.62%
Kymera Therapeutics
Dec 9, 2025
Maintains: Overweight
Price Target: $73 → $127
Current: $82.71
Upside: +53.55%
Novartis AG
Sep 12, 2025
Downgrades: Sell
Price Target: $119 → $118
Current: $145.50
Upside: -18.90%
Sanofi
Mar 21, 2025
Initiates: Neutral
Price Target: $65
Current: $43.36
Upside: +49.91%
Grifols
Dec 5, 2023
Maintains: Neutral
Price Target: $10 → $11
Current: $8.27
Upside: +26.96%
Galapagos NV
Aug 7, 2023
Maintains: Equal-Weight
Price Target: $42 → $40
Current: $28.39
Upside: +40.89%
Evotec SE
Jun 23, 2023
Upgrades: Overweight
Price Target: $12 → $16
Current: $3.20
Upside: +400.00%